about
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulatorsOsteoprotegerin rich tumor microenvironment: implications in breast cancerKey roles of the OPG-RANK-RANKL system in bone oncologyDifferential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.Development of a multimarker assay for early detection of ovarian cancer.Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation.Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasisAcademic pharmacy strikes Hawai'i. Part 2.Rab25 Small GTPase Mediates Secretion of Tumor Necrosis Factor Receptor Superfamily Member 11b (osteoprotegerin) Protecting Cancer Cells from Effects of TRAILEnhancement of periodontal tissue regeneration by transplantation of osteoprotegerin-engineered periodontal ligament stem cellsOsteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.Osteoprotegerin mediates tumor-promoting effects of Interleukin-1beta in breast cancer cells.Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines.Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension.The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis.The role of the bone microenvironment in skeletal metastasis.Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patientsRANKL/RANK/OPG: key therapeutic target in bone oncology.Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor geneEvidence for a calcification process in the trabecular meshworkAkt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.Therapeutic implications of osteoprotegerin.Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis.Osteoprotegerin expression during the micro- and macrometastatic phases of the osteoblastic metastasis in prostate cancer: therapeutic implications.Mechanical instability and titanium particles induce similar transcriptomic changes in a rat model for periprosthetic osteolysis and aseptic loosening.Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma.Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment.The presence of TRAIL-OPG complex in human osteosarcoma and human salivary gland adenocarcinoma.Tumor-related interleukins: old validated targets for new anti-cancer drug development.The role of serum osteoprotegerine in metastatic prostate cancer - a case control study.Mechanistic study of the proangiogenic effect of osteoprotegerin.Prognostic Value of Osteoprotegerin and sRANKL in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer.cDNA cloning and characterization of a new member of the tumor necrosis factor receptor family gene from scallop, Chlamys farreri.Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy.Recurrent amplification of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer.The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer.
P2860
Q24336898-D575FC73-48F9-41DA-AF88-7E9223B68C35Q26748804-681064C2-9E66-493A-B086-40303500BA98Q28287394-5F0C3801-F538-4C8F-B027-2D901171BA5AQ30412235-08B7EE01-4CAA-40F2-9C5D-AAC87AB06E3DQ33421148-1AD304A4-67F2-4B0E-B7C5-BE9AEF348F0BQ33813724-84B1AE99-ED10-413B-B5AD-9CFBF801FA73Q33944881-A978E883-E781-48D5-9390-DF37E8825191Q34147824-4B96293C-086E-456F-ABDB-F82643740EF4Q34469273-43C43911-03D2-48EF-89E3-8CAF86B6510FQ34700466-8351E498-83A8-405A-9F17-2F2268ECC0EBQ35588448-FFF72703-89D7-4BD3-8D8E-90F43FB5D005Q35853271-B848E730-3869-4E51-8C05-18B1FA102F3EQ36265801-C088785B-80B4-4A0B-BA65-7D902964CC99Q36338510-5B5727E1-9466-497D-AB28-FA40D39A6ED3Q36340848-31A3B282-1791-4534-BC4A-F0999D90D965Q36357434-762804EC-BE76-4BDA-8F4F-9683A49DADF5Q36376105-B4D0C110-F2AB-4CD4-B2AD-1CCE3D3DB9DDQ36491430-C1CF9175-02A1-479D-92EE-A4EBAFC183DEQ36502817-3F0F8430-EED0-41FE-B4DC-1EA080BDEF38Q37140665-E4C04576-E007-4198-A958-B5F6A1A73127Q37149062-67346BB2-7E6A-4EF7-8AE5-97F46A1450D8Q37163213-4C614AB5-9217-44FB-9984-BEA91C9937D9Q37273453-1E077276-FDAF-4F4E-BB4E-BB22B4C667DBQ37368570-7F15587B-B0A8-4042-A90C-C739267AC34BQ37409192-9230691F-91D9-4F77-AD63-2A6A7F7F2427Q37694788-1A001628-4F10-421C-B280-E72FAA36E348Q38136300-46968EF3-8536-4645-AB86-D08980E115ACQ38631292-CA8FBD43-FAE8-4511-9F0B-931D090789C2Q38741874-F732DD52-5897-499F-BB74-7433DAAB6569Q38938230-BF1105D0-53FD-41FA-9D78-95308FD94E98Q39054114-B7C30860-92A2-4F51-9F67-369A07EEEDDAQ39604830-703A6C55-6361-4F57-88CA-3E2A73BEBF4BQ41716360-5E4F4087-0DA1-400F-99CC-4A7BA8A1B9FDQ42292052-8776DB98-F41C-4B19-89E0-C18D55EB1288Q43938558-F856F365-CC3B-4C38-AA99-DDF4B4DD7D80Q47738511-F015A855-8FA6-43EF-AEAB-75491A80B561Q48061286-D5973408-D89A-4F96-93B4-A8C5E0D3DC97Q50947041-D586C0CE-91BD-4DC0-A352-3DAE4D71BEE7Q53636235-190F2CB5-F5E8-4DD2-8EAE-E69CFE83B539Q53807792-94B8FC15-156B-453A-9B2D-6BFC6F4C0BDB
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Role of osteoprotegerin (OPG) in cancer.
@ast
Role of osteoprotegerin (OPG) in cancer.
@en
type
label
Role of osteoprotegerin (OPG) in cancer.
@ast
Role of osteoprotegerin (OPG) in cancer.
@en
prefLabel
Role of osteoprotegerin (OPG) in cancer.
@ast
Role of osteoprotegerin (OPG) in cancer.
@en
P356
P1433
P1476
Role of osteoprotegerin (OPG) in cancer.
@en
P2093
Claire M Shipman
Ingunn Holen
P304
P356
10.1042/CS20050175
P407
P577
2006-03-01T00:00:00Z